Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for ZYNLONTA + Rituximab in Blood cancer, Follicular lymphoma. The expected timing is based on the latest available company guidance and may change.
12/12/23 Initial positive results presented at ASH. Planning a multicenter clinical trial to expand the current cohort, to launch in Q1 '24. 11/5/24 Additional updates at ASH medical congresses on 12/7/24. 11/10/25:- iwNHL Ph2 IIT update; ORR 98%, CR 84%; median PFS not reached; trial expanded to 100 patients. 03/10/26:- Data publication between end-2026 and mid-2027. 05/04/26:- IIT FL and MZL trials ongoing; data publication still expected between end-2026 and mid-2027. 08/13/26:- Updated FL Phase 2 IIT data will be presented in Q2 2027.
Verification
Confirm timing and program details against the company announcement or filing.